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The physicochemical characterization of the magnetoferritin biomacromolecule in 
terms of morphology, structural and magnetic properties shows that iron oxides can be 
efficiently loaded into apoferritin molecules, preserving their native, bio-compatible structure 
and  affecting the morphology of the protein shell.  
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Natural ferritin is the iron-storage protein of animals, plants, and bacteria. It is a spherical 
biomacromolecule of external diameter about 12 nm composed of 24 protein subunits 
arranged as a hollow sphere of approximately 8 nm in diameter. Inside the sphere, iron is 
stored in the ferric oxidation state as complex molecule with a crystallographic structure 
similar to the mineral ferrihydrite [1]. By a suitable chemical process, magnetic iron oxide 
nanoparticles (Fe3O4, γ−Fe2O3) can be synthesized in the empty protein shell of ferritin, i.e. 
apoferritin, forming a biocompatible ferrofluid, called magnetoferritin [2,3]. The problem of 
toxicity and side effects of magnetic nanoparticles in organs and tissues is minimized due to 
the protein nature of this material, which is important for many possible applications in cell 
labeling, biological separation and clinical practice. Their magnetic properties, based on their 
inducible magnetization, allow them to be heated by externally applied AC magnetic field. It 
makes them attractive for many applications, ranging from various magnetic separation 
techniques and contrast enhancing agents for MRI to magnetic hyperthermia [4, 5]. 
Magnetoferritin is a promising compound which can be used as a drug carrier; the protein 
shell is able bind to tumor cells via transferin receptor 1 (TfR1) [6] and the drug can be bound 
to the protein subunit. In addition to biocompatibility, another advantage for biotechnological 
applications of magnetoferritin is a relatively short time of controlled synthesis [7, 8]. 
 The main interest of the present study is associated with understanding of certain diseases 
development mechanism that is in a close relationship with the iron metabolism and iron 
storage protein, ferritin [9]. In healthy organisms, ferritin is able to store up to 4500 Fe atoms 
in a ferrihydrite-like mineral core [10]. Many researchers confirmed the presence of magnetite 
nanoparticles inside pathological tissues [11, 12] which is related to the Fe
2+
 ions 
  
accumulation and defects in the normal storage function of ferritin [13]. This indicates the 
transformation of ferrihydrite to magnetite and formation of biogenic magnetoferritin. The 
precise mode of such transformation regulated by the biochemistry of organisms (presence of 
specific enzymes, bio-complexes, etc.) has not been determined yet. Therefore, in this 
research, magnetoferritin prepared by in vitro chemical synthesis was used as a model system 
of pathological ferritin. Structural studies of ferritin and magnetoferritin would be useful to 
elucidate the structural changes of ferritin shell disruption or aggregation which is observed in 
development of many cancer or neurodegenerative diseases [14, 15].  
 In this study, magnetoferritin prepared by controlled chemical synthesis, in accordance 
with a procedure described previously [16] was the test material characterized by dynamic 
light scattering (DLS), transmission electron microscopy (TEM), small-angle neutron and X-
ray scattering (SANS, SAXS) and SQUID magnetometry. 
 The zeta potentials of the test apoferritin and magnetoferritin at comparable 
concentrations of 2.11 mg/ml and 2.36 mg/ml were -25.5 mV, -21.9 mV respectively. The 
results confirm the negative charge of the molecule and its good stability. The hydrodynamic 
diameter of magnetoferritin molecules was measured and compared with that of apoferritin by 
dynamic light scattering technique with protein concentration of 0.3 g.L
-1
 in both solutions 
(Fig. 1.).  
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Fig. 1.The size distributions of apoferritin and magnetoferritin as revealed by DLS 
 
Generally, the hydrodynamic diameter is larger than the theoretical size because it 
indicates the effective size of the hydrated/solvated molecule. In comparison with apoferritin 
hollow sphere (<DHYDR> = 14.14 nm), the hydrodynamic diameter of magnetoferritin 
increases (<DHYDR> = 19.54 nm). Such increase can be related to a deformation of the 
particles upon loading with iron oxide and to the presence of some fraction of aggregated 
particles. 
 Transmission electron microscopy showed presence of well-defined rounded 
nanocrystallites (Fig. 2.) with average diameter of 5 nm. 
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Fig. 2. TEM image of magnetoferritin 
 
The electron diffraction of magnetoferritin samples confirmed the face-centered cubic 
crystalline structure of the ferrous phase but it is not possible distinguish between magnetite 
(Fe3O4) or maghemite (γ−Fe2O3). More information can be obtained by magneto-optical 
birefringence or Faraday rotation studies as was shown in our recent works [17,18].  
 Small-angle neutron scattering measurements were performed at the Yellow 
Submarine instrument operating at the Budapest Neutron Centre [19]. Samples were prepared 
by redispersing apoferritin and magnetoferritin in D2O from dry powder to form a 2 wt. 
percent solution. 
 
 
  
 
 
 
 
 
 
 
Fig. 3. SANS data of magnetoferritin and apoferritin dispersions in D2O. The solid lines are 
model fits of a spherical shell to the apoferritin data and the same model including aggregated 
particles for the magnetoferritin data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Field dependence of magnetoferritin magnetization measured at room temperature. 
 
  
Fig. 3. compares the scattering data from pure (unloaded) apoferritin with the scattering of 
magnetoferritin. For both solutions, the minima and maxima characteristic to the spherical 
shell form factor of apoferritin are seen. For magnetoferritin, the oscillations are less 
pronounced, indicating that the spherical form of the protein is only partly preserved. The 
relative weakening of the characteristic shell structure is attributed to a deformation of the 
protein shell upon loading, leading to decrease in the spherical symmetry of the molecules. 
The increase in the scattering intensity at small values of q shows that a fraction of the 
molecules aggregate to loose objects of sizes larger than 200 nm. The experimental data were 
modeled using the hollow spherical shell model of apoferritin and aggregated spherical shell 
particles for the case of magnetoferritin. The solution contains both aggregated and non-
aggregated particles, and the used modeling could not distinguish these populations; therefore 
the fraction of aggregated particles could not be extracted from the data. Small-angle X-ray 
scattering data, taken using a laboratory setup, confirmed that the aggregates contain iron 
oxide. 
 Magnetic properties of magnetoferritin were investigated using SQUID magnetometer 
in magnetic fields up to 4 000 kA.m
-1
. The samples show superparamagnetic behavior without 
hysteresis at room temperature (Fig. 4). Using the particle size as obtained by TEM, and 
assuming magnetite, the saturation magnetization of 8 A.m
2
.kg
-1
 was calculated. The 
observed magnetization is by an order of magnitude lower than this value, indicating that the 
magnetic core of magnetoferritin presumably consists of mixed hematite and magnetite. The 
magnetization curves measured at 2K below blocking temperature (Tb = 26 K) showed the 
hysteresis with coercive field of 20.0 kA.m
-1
. The magnetization measured at 5 K undergoes a 
slow approach to saturation at field which we can achieve.  
In conclusion, the synthesized materials demonstrate a superparamagnetic behavior, 
the structure determined by TEM and scattering shows that magnetic nanoparticles are 
confined in the spherical protein shell with particle diameters about 5 nm, thus, not filling the 
entire available space. The protein structure slightly changes upon loading, and this change 
can be attributed to the effect of iron oxides binding and ordering inside the protein cavity of 
magnetoferritin. Further experiments, for example, contrast variation SANS methods would 
give more detailed information concerning the protein and the magnetic structure of 
magnetoferritin with different loading factors, to reveal how the iron oxides affect protein 
conformation. Clarification of these effects could have a major impact in biomedicine for 
understanding the role of magnetite in connection with aggregation process in the 
development of neurodegenerative diseases. 
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